Download Sample
Schedule a Meeting
Table of Content
NA : +1 804 441 9344
sales@towardshealthcare.com
September 2025
The hepatitis A vaccine market was estimated at US$ 742.31 million in 2023 and is projected to grow to US$ 948.16 million by 2034, rising at a compound annual growth rate (CAGR) of 2.25% from 2024 to 2034. The increasing outbreaks of hepatitis A, increasing awareness about immunization, and increase in travel and tourism.
The Hepatitis A vaccine prevents hepatitis A, an infectious liver disorder caused by the hepatitis A virus. It is given to children 12-23 months old as part of their routine childhood vaccination. The Centers for Disease Control and Prevention (CDC) recommends vaccinating people with chronic liver disease, treating people with clotting factor concentrates, working close to the virus, and living in communities where an outbreak is present. Hepatitis A vaccine is effective for at least twenty years or possibly a person’s entire life.
The increasing outbreaks of hepatitis A and rising incidences of HIV and chronic liver disease increase the need for hepatitis A vaccines. According to the WHO, around 354 million people globally are estimated to be suffering from hepatitis A, with 1.3 million deaths. Additionally, favorable government policies and WHO guidelines for immunization boost the market.
The major growth factor for the Hepatitis A vaccine market is the increasing immunization campaigns by government and private agencies. The World Health Organization (WHO) strategizes to guide the health sector (2022-2030) to implement strategically focused responses to achieve the goals of ending AIDS, viral hepatitis, and sexually transmitted infections by 2030. Immunization programs create awareness among the general public to vaccinate their children. Some government organizations in underdeveloped and developing countries provide free vaccinations to children from low-income groups.
Hepatitis A is an inflammation of the liver caused by the hepatitis A virus, which can result in mild to severe illness. The virus is spread when an uninfected (or nonvaccinated) person ingests food or water contaminated with the feces of an infected person. Hence, the disease spreads due to unsafe water or food, inadequate sanitation, and poor personal hygiene. People traveling to multiple countries are at a higher risk of getting infected with the disease. The most prone geographical areas with a high risk of hepatitis A virus circulating in the local population include Africa (except South Africa), Eastern Europe, and Asia. According to the United Nations report on tourism, an estimated 1.3 billion international arrivals were reported in 2023. Most of the traveling was in the Middle East, Europe, and Africa. The CDC recommends that infants 6 through 11 months old traveling outside the US should receive one dose of hepatitis A vaccine, and adults with high traveling across various countries should also receive the vaccine.
Hepatitis A vaccine manufacturers face several challenges related to manufacturing. The high cost of hepatitis A vaccine manufacturing is attributed to the installation of necessary technology and favorable infrastructure. The demand for a balance between meeting global healthcare needs and minimizing environmental impact poses a significant challenge for sustainable manufacturing of hepatitis A vaccine. The scale-up of vaccine manufacturing requires huge amounts of antibodies, viral vectors, and pathogens. Also, the supply chain functioning for all essential components with proper cold chain logistics troubles the scale-up of vaccine manufacturing.
Asia-Pacific dominated the hepatitis A vaccine market in 2023. The rising incidences of hepatitis A, favorable government policies, increasing investments & collaborations, and increasing awareness drive the market. In India, over 2,400 confirmed cases and 18 confirmed deaths were reported as of May 2024. China reports 975 cases of hepatitis A as of January 2024. Asia-Pacific is the predominant region with a high epidemiology of hepatitis A. Several government organizations in the region conduct immunization campaigns to spread awareness, thereby encouraging people to get a hepatitis A vaccination. The Indian Government’s “Make in India” policy promotes indigenous manufacturing of hepatitis A vaccines. China is the only country developing, manufacturing, and distributing live attenuated hepatitis A vaccines. According to a WHO report, China represents one of the largest global demands (22%) for hepatitis A vaccines.
North America is anticipated to grow fastest in the hepatitis A vaccine market during the forecast period. The presence of key players, state-of-the-art manufacturing infrastructure, and favorable government policies drive the market. The major global players of hepatitis A vaccine manufacturers, such as GSK, Johnson & Johnson, and Merck, are located in the US. It was estimated that around 13 million doses of the total global demand of 37 million doses were utilized by 16 countries of The Regions of America (AMRO). The Canadian Government provides free hepatitis A vaccines to infants, children, and adults at high risk of infection or spread of the virus. The National Advisory Committee on Immunization (NACI) serves as an advisory body on the use of vaccines in Canada. Hence, such government organizations potentiate the market.
By type, the inactivated vaccine segment registered its dominance over the global. This segment dominated because the inactivated hepatitis A vaccine contains hepatitis A antigen inactivated virus. This promotes the body to produce antibodies against the antigen, developing immunity. These vaccines are more stable than the live ones. Also, they cannot convert into virulent forms, cause disease, and do not replicate. Hence, inactivated hepatitis A vaccines are widely preferred.
The live attenuated vaccine segment is expected to grow fastest in the hepatitis A vaccine market during the forecast period. Live attenuated hepatitis A vaccine contains a live, inactivated form of the virus. There are at least two live attenuated vaccines available globally in the market. It produces a robust immune response for long-lasting immunity.
By application, the government institution segment led the global market. This is due to government institutions are at the forefront of providing vaccines at affordable costs. The government conducts several immunization programs and awareness programs for hepatitis A vaccines.
The private sector segment is predicted to witness significant growth in the market over the forecast period. The private sector is an important contributor to immunization services. High capital investment by the private sector in manufacturing and distributing vaccines at a global scale boosts the segment growth.
Luke Miels, Chief Commercial Officer, GSK, commented that the revised agreement with Zhifei puts GSK’s collaboration on a sustainable footing, managing challenges in the macro environment in the near-term, and helping the company to reach even more Chinese people with its innovative adult vaccines over the long-term.
By Type
By Application
By Region
September 2025
September 2025
September 2025
September 2025